INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.

Acadia said Phase 2 topline results for remlifanserin at 60 mg narrowly missed the primary endpoint in its ongoing RADIANT program for Alzheimer’s disease psychosis. Acadia shares fell 12.78% to $22.18 on September 24, 2026, then dropped another 6.76% to $20.68 on September 25 after multiple analyst downgrades. Pomerantz LLP announced an investigation into possible securities-law violations; the claims are allegations, not established findings.

Analysis

The key risk is a lower probability of meaningful Alzheimer’s psychosis revenue from remlifanserin—not the law firm’s investigation, which is a common follow-on to a sharp share-price decline and adds little absent evidence of a disclosure failure. The endpoint miss may also constrain the Phase 3 design: a marginal signal can require larger trials, tighter patient selection, or a dose strategy that takes longer to validate. That raises development cost and delays any commercial contribution, while leaving uncertainty around whether secondary endpoints or subgroup data preserve a viable path.

Near term, expect volatility around full results, management’s interpretation, and any revised Phase 3 plan. Over 1–3 months, watch for protocol changes, regulator feedback, and analyst revisions to pipeline value. Over 6–18 months, the central question is whether the program can produce a reproducible, clinically meaningful effect; failure would remove optionality, while a credible redesign could recover some value. Existing treatment alternatives could limit adoption even if efficacy is ultimately demonstrated.

Contrarian angle: the two-day repricing may already discount a substantial reduction in program value, so a fresh outright short risks a data-driven rebound. The lawsuit itself is not a catalyst unless specific evidence emerges. The thesis is weakened by convincing secondary-endpoint or subgroup results and a feasible Phase 3 plan; it is strengthened by weak full-data detail, a delayed or materially redesigned trial, or further pipeline-value cuts.

Key Decisions for Investors

• Avoid initiating a new outright short solely on the litigation headline. For a bearish biotech book, consider an ACAD underweight or a small relative-value short versus a diversified biotech exposure, sized for binary clinical-data risk.
• Wait for the complete RADIANT dataset and management’s Phase 3 plan before adding downside exposure. If results fail to support a credible path and ACAD rebounds, consider a defined-risk put spread rather than paying potentially elevated outright option volatility.
• Treat the investigation as a watch item, not a standalone trade: reassess only if filings or credible evidence identify a specific disclosure issue. The current report does not establish misconduct or quantify legal exposure.
• Falsifiers to monitor: supportive secondary or subgroup efficacy, regulator alignment on a practicable Phase 3 design, or guidance preserving the program’s timeline. Red flags are trial delay, a materially expanded or altered study, or further reductions in pipeline expectations.